POET Technologies and BAE Systems sign collaboration agreement

POET Technologies Inc. {TSX-V: PTK} Announced the Signing of a Collaboration Agreement with BAE Systems, the formation of a Technology Road-map Advisory Board, and corporate Updates.

The agreement with BAE Systems will ebable the advancement of the technology in a world class facility, and endorses POET's credibility within their field of expertise.

Toronto, ON, and Storrs, CT, March 30, 2015 – **POET Technologies Inc. {TSX-V: PTK}** developer of the planar opto-electronic technology ("POET") platform for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single semiconductor wafer – today announced the signing of a collaboration agreement with BAE Systems Microelectronics and corporate updates, in particular the formation of a "Technology Road-map Advisory Board".

Collaboration Agreement with BAE

POET Technologies Inc. signed a contract with BAE Systems under which BAE Systems will provide non-exclusive third-party foundry services in support of the Company's "Lab-to-Fab" transition plan. The current phase of the work will be performed between March 2015 and August 2015. Key objectives of the collaboration include process transfer, prototype builds and design enablement kit development. Using BAE Systems' ISO Certified manufacturing facility will improve the quality, process control and analytical capacity of prototype builds. The result will be both a more manufacturable process

and improved optimization of the device structures included in the POET technology.

Initial phases of the program will be performed using 3-inch wafers but from the onset the program will work towards the objective of achieving the full process flow on 6-inch wafers. Virtually all production GaAs-based processes are currently manufactured using 6-inch wafers. The Company believes that using BAE Systems' manufacturing and test capabilities will help the Company to build devices that dramatically demonstrate the disruptive nature of the technology.

"The POET technology incorporates silicon processes into GaAs integrated circuits, producing multifunction chips such as photonics and electronics that will provide enhanced commercial and military products," said Dr. P.C. Chao, Technical Director at BAE Systems. "Working with BAE Systems will enable the acceleration and maturation of the POET fabrication process for a faster prototype demonstration and a smoother transition to manufacturing."

Mr. Daniel DeSimone, POET's Chief Technology Officer noted: "*Our agreement with BAE Systems is a significant step in our "Lab-to-Fab" transition. BAE Systems has a long history of high quality manufacturing with III-V materials, and brings process development expertise and manufacturing discipline to the relationship. We have collaborated with BAE Systems numerous times over the last 2 years, most recently to successfully transfer our most critical process loop into their facility. Encouraged by this track record, we are excited to be extending this collaboration to develop the full flow on 3-inch and later 6-inch wafers.*"

Formation of Technology Roadmap Advisory Board

The Company announces the formation of a "Technology Roadmap Advisory Board" comprising of Dr. Geoff Taylor, Ajit Manocha,

and Tony Blevins. This Advisory Board collectively has extensive expertise in the semiconductor industry, supply chain management and operations, consumer products, and key technology markets, with over 100 years of combined experience.

This Advisory Board will act as advisors to the Board of Directors and the Executive team with primary focus on optimizing and accelerating the company's "Lab-to-fab" transition and commercialization plans. "The Company is looking forward to leveraging the newly formed Advisory Board's semiconductor market expertise and execution track record," said Mr. Peter Copetti, Executive Co-Chairman and interim CEO.

Further Updates

The Company intends to provide a full financial update with the filing of annual audited financial statements and Management Discussion and Analysis which will be issued in April. Further details of the aforementioned third party services contract will be provided at that time.

Option Grant

The Board approved the grant of 500,000 stock options to Mr. Daniel DeSimone, pursuant to the Company's stock option plan. Pursuant to TSX Venture Exchange policies, and based on market price, the exercise price of the options was at CA$1.65 per share and expire on March 30, 2020. The options will vest and be exercisable on the basis of 25% six months after the date of issue and 25% every six months thereafter. Dr. Geoff Taylor, POET's Chief Scientist noted: "*Dan has been instrumental in recent successes and has advanced our engineering discipline and process methodology, benefiting our*

process IP development and prototype milestone activities."

About POET Technologies Inc.

POET Technologies is the developer of the POET platform for monolithic fabrication of integrated circuit devices containing both electronic and optical elements on a single semiconductor wafer. With their head office in Toronto, Ontario, Canada, and operations in Storrs, CT, the Company, through ODIS Inc., a U.S. company, designs III-V semiconductor devices for military, industrial and commercial applications, including infrared sensor arrays and ultra-low-power random access memory. The Company has several issued and pending patents for the POET process, with potential high speed and power-efficient applications in devices such as servers, tablet computers and smartphones.

The Company's common shares trade on the **TSX Venture Exchange** under the symbol "**PTK**" and on the **OTCQX** under the symbol "**POETF**".

For more information please visit our websites at **www.poet-technologies.com**

ON BEHALF OF THE BOARD OF DIRECTORS
Michel Lafrance, Secretary

Inovio Pharmaceuticals Announce $76 million financing

Inovio Pharmaceuticals (NASDAQ: INO} have announced at $76 million gross fundraising at $8 per share.

They are issuing 9,500,000 new shares, with an over allotment of 1,425,000 available to the underwriters under a 30 day option.

Inovio Pharmaceuticals Announces Pricing of Public Offering of Common Stock

PLYMOUTH MEETING, PA – April 30, 2015 – **Inovio Pharmaceuticals, {Nasdaq: INO}**, today announced the pricing of an underwritten public offering of 9,500,000 shares of common stock for a public offering price of $8.00 per share. The gross proceeds to Inovio from this offering are expected to be $76,000,000, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company.

The Company has granted to the underwriters participating in the offering a 30-day option to purchase up to an additional 1,425,000 shares of common stock. The offering is expected to close on or about May 5, 2015, subject to customary closing conditions.

The Company intends to use the net proceeds received from the sale of the common stock for general corporate purposes, including clinical trial expenses, research and development expenses, general and administrative expenses, manufacturing expenses and potential acquisitions of companies and technologies that complement its business.

Piper Jaffray & Co. and Stifel are acting as joint bookrunning managers for the offering. H.C. Wainwright & Co., LLC, Brean Capital, LLC and Maxim Group LLC are acting as co-managers of the offering.

The securities described above are being offered by Inovio pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (the "SEC") on August 8, 2014. The offering will be made only by means of the written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the securities being offered may also be obtained from Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, via telephone at 800-747-3924 or email at prospectus@pjc.com; or from Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, via telephone at 415-364-2720 or email at syndprospectus@stifel.com.

This press release does not constitute an offer to sell or the solicitation of offers to buy any securities of Inovio being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and

infectious diseases. Their immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit **www.inovio.com.**

CONTACTS:

Investors: Bernie Hertel
Email : bhertel@inovio.com

* * *

This press release contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995 relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including that the offering is subject to customary closing conditions, and uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be

completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company’s technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio’s pipeline will be successfully developed or manufactured, that final results of

clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

City Investors Circle welcomes active investors

City Investors Circle is an established group of investors focused on growth companies in their early stages of development.

If you actively manage your own investment portfolio, and are interested in meeting the CEO’s of exciting growth companies, email rhea@city-investors-circle.com to register your interest in attending future meetings.

City Investors Circle meets in the financial district of the City of London, on a regular basis, and present growth companies in their early stages before they appear on the radar of the mainstream media and brokers, giving attendees first mover advantage on a good story.

We utilise superb facilities, serve complimentary food and wine,and treat all our investors as friends.

The networking is an important part of each presentation, and affords newcomers the opportunity to chat to city professionals and high net worth individuals in an informal setting.

If you think you could benefit by meeting CEO's and city professionals, join the circle!

Email : **rhea@city-investors-circle.com** to receive our newsletter and invitations to all our events.

We promise you a warm and friendly welcome when you arrive for a meeting!

Scorpio terminates $15 million financing due to large shareholder concerns

Scorpio Gold Corp. {TSX.V: SGN} surprised the market by announcing that the recently announced $15 million financing with NY based Coral Reef Capital LLC has been terminated.

This follows concerns expressed by certain large shareholders, and will result in Scorpio having to pay a termination penalty fee.

News – Tuesday, April 28, 2015
Scorpio Gold Provides Update on the Previously Announced $15 Million Strategic Financing

---

Vancouver, April 28, 2015 – **Scorpio Gold Corporation {TSX-V: SGN}** announces that the proposed $15 million Strategic Financing with Coral Reef Capital LLC has been terminated due to concerns about certain large shareholders opposing the

transaction.

As such, the Company is obligated to pay a break fee of $500,000 along with approximately $100,000 of related due diligence costs incurred by Coral Reef.

The Company is currently analysing alternative financing opportunities including a possible debt financing with Coral Reef, which is at an advanced stage of negotiation.

Further details will be released when available.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
CEO

For further information contact:
Peter J. Hawley, CEO
Tel: (819) 825-7618
Email: phawley@scorpiogold.com

Website: www.scorpiogold.com

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company's current expectations and estimates. Forward-looking statements are frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate", "suggest", "indicate" and other similar words or statements that certain events or conditions "may" or "will" occur, and include, without restriction, any statements regarding the Company plans with respect to the exploration, development and exploitation of its Mineral Ridge project and its Goldwedge

property and mill, or its financing plans. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mineral exploration and development programs, risks involved in mineral processing, risks involved in obtaining financing; and those risk factors outlined in the Company's Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

Scorpio announces commencement of underground

drilling at Goldwedge

Vancouver, B.C. – Apr 27, 2015) – **Scorpio Gold Corporation {TSX.V: SGN}** announces the commencement of underground exploration drilling, and results from its 2014 surface drilling program, at the Company's 100% owned Goldwedge project, located in Manhattan, Nevada.

The Company recently commenced a 5,000 ft (1,524 m) underground drilling program encompassing a planned 23 NQ diameter core holes drilled from 7 underground stations. The goal of the program is to test the Company's revised geological model, which is based on new structural and lithological data obtained from the Company's 2014 surface drilling and geological mapping program. The 2015 underground holes are designed to intersect perpendicular to the N60W trending mineralized zones, providing better information for ongoing geological modelling that will in turn guide future exploration drilling. Completion of the program is expected in Q2 2015 with analytical results available later in 2015.

The Goldwedge project includes a fully permitted underground mine with over 600 meters of underground development and a mill facility with gravity circuit that is currently permitted to process 400 tons per day. Geologically, the Goldwedge deposit lies within the Walker Lane Gold Belt and is situated on the southern periphery of the Manhattan Caldera, approximately 16 kilometers south of the operating Round Mountain Mine. Several styles of gold mineralization have been documented at Goldwedge, from fault breccia and vein hosted to strata-bound replacement style in limestone and pervasive quart-sericite-pyrite alteration hosted.

In 2014, Scorpio Gold drilled four surface oriented core holes to gain further knowledge of the Goldwedge geology and controls to the mineralization. The orientation of the holes was based on the historical interpretation that mineralization

was controlled by N30W trending structures which paralleled the regionally significant Reliance Fault Zone. Information gained from the 2014 drilling, in conjunction with surface and underground mapping, has led to the re-interpretation that the primary structural control to mineralization actually trends N60W.

Significant results from the 2014 drilling are presented on the Scorpio website – http://www.scorpiogold.com/s/news.asp?ReportID=705089 All holes presented were completed by diamond (core) drilling. Widths are presented as down hole core lengths; true widths are unknown at this time. Analytical results were performed by ALS Chemex in Reno, Nevada, an ISO/IEC 17025:2005 accredited testing laboratory. Further details are presented in the Company's quality assurance and quality control program for the Goldwedge project at at: GW QAQC.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%), and Scorpio Gold is currently entitled to receive 80% of cash flow generated. Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property and processing facility in Manhattan, Nevada. The Company has commenced its 2015 exploration program for the Goldwedge property and is currently processing limited quantities of high-grade Mineral Ridge ore at the Goldwedge plant, which is permitted to process 400 tons per day.

Scorpio Gold’s CEO, Peter J. Hawley, PGeo, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD, SCORPIO GOLD CORPORATION

Peter J. Hawley, CEO

The Company relies on litigation protection for forward-looking statements. This news release contains forward-looking statements that are based on the Company’s current expectations and estimates. Forward-looking statements are frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “suggest”, “indicate” and other similar words or statements that certain events or conditions “may” or “will” occur, and include, without restriction, any statements regarding the Company plans with respect to the exploration, development and exploitation of its Mineral Ridge project and its Goldwedge property and mill. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual events or results to differ materially from estimated or anticipated events or results implied or expressed in such forward-looking statements, including risks involved in mineral exploration and development programs, risks involved in mineral processing; and those risk factors outlined in the Company’s Management Discussion and Analysis as filed on SEDAR. Any forward-looking statement speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking

statement, whether as a result of new information, future events or results or otherwise. Forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty thereof.

Contact:
Scorpio Gold Corporation
Steve Roebuck. President
1 819 825-7618
sroebuck@scorpiogold.com

Inovio receive complaint from former merger managing director

Inovio Pharmaceuticals {NASDAQ: INO} have ,according to legal website Law360, been in receipt of a complaint from the former managing director of a pharma company they merged with in 2009.

The complaint was filed in a New Jersey Court.

Please note this has been reported by a legal website, and not yet confirmed by Inovio.

Law360, New York (April 24, 2015) – A former managing director of a pharmaceutical company that merged with **Inovio Pharmaceuticals Inc.{NASDAQ: INO}** in 2009 has filed a complaint in New Jersey state court against Inovio, contending he was wrongly blocked from exercising certain stock options after the merger.

Keele Park alleges in the Wednesday complaint that Inovio, a Delaware-based pharmaceutical company that develops vaccines for cancers and infectious diseases, and company CEO J. Joseph Kim have breached a 2006 agreement that should have allowed him to purchase 150,000 shares of common stock.

Scorpio Gold sets quarterly production record at Mineral Ridge

Scorpio Gold {TSX.V: SGN} sets a Quarterly Production Record at their Mineral Ridge Operation, Nevada.

With production of 11,952 ounces of gold in the first quarter, Scorpio Gold exceeded the first quarter 2014 by some 16%. Silver production increased by some 23% over the same period.

Comment

Once again Scorpio Gold bring out positive news, but the continual positive newsflow is sadly not being recognised in a harsh market.

In better times, in production, with low costs, in a good jurisdiction, with an experienced management team, and this stock would be adding shareholder value, but in the current climate it is one to follow until gold starts to rise.

News Release

Vancouver, April 23, 2015 – **Scorpio Gold Corporation {TSX-V: SGN}** announces its operating results for the first quarter ("Q1") of 2015 at its 70% owned Mineral Ridge project, located in Nevada.

Gold production in Q1 2015 totalled 11,952 ounces, representing a 16% increase over Q1 2014 and a new quarterly production record for the Mineral Ridge operation. Silver production totalled 6,319 ounces, representing a 23% increase over Q1 2014 and also a record high for Mineral Ridge.

Peter J. Hawley, CEO, reports, "*We are very pleased to report a new quarterly production record at Mineral Ridge. While we are currently cycling through lower grade material in the Mary pit, our gold production continues to be aided by the drawdown of ounces from the leach pad inventory and by ongoing efforts to re-slope the periphery of the leach pad to bring previously un-leached material under leach. This is a strong start to the year and puts Scorpio Gold in a very good position to meet our 2015 production forecast of 40,000 to 45,000 ounces of gold*."

In 2014, batch processing of Mineral Ridge ore was initially undertaken at the Company's 100% owned Goldwedge mill facility on a test basis to optimize the milling circuit for the recovery of coarse gold. Scorpio Gold continued to process high-grade ore from Mineral Ridge at Goldwedge in Q1 2015 in order to globally increase the gold recovery with the processing of 1,392 tonnes of Mineral Ridge ore grading on average 8.87 g/t gold. The ounces processed at Goldwedge during Q1 2015 are not included in the total ounces produced for the first quarter as they were still considered in-process as of March 31, 2015. Accordingly, they will be accounted for in the second quarter production results.

Production in 2015 is scheduled from the Mary and Mary LC pits, and from the Wedge, Bluelite, Solberry and Brodie satellite pits. Mining at the Bluelite and Solberry pits is scheduled to commence in Q2 2015. The Bluelite and Solberry

deposits have not been subject to any prior mining campaigns, hence their high-grade core zones are preserved and expected to positively impact the grade of ore being processed at both the Mineral Ridge and Goldwedge mill facility.

For full production results – http://www.scorpiogold.com/s/news.asp?ReportID=704576

(1) A weighted average metallurgical recovery factor has been applied to the estimated contained ounces crushed and placed on the leach pad, based on the pit from which the ore was mined.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%), and Scorpio Gold is currently entitled to receive 80% of cash flow generated. Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property and processing facility in Manhattan, Nevada. The Company is preparing its 2015 exploration program for the Goldwedge property and is currently processing high-grade Mineral Ridge ore at the Goldwedge plant, which is permitted to process 400 tons per day.

Scorpio Gold's CEO, Peter J. Hawley, PGeo, is a Qualified Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
CEO

For further information contact:
Steve Roebuck, President
Tel: (819) 825-7618
Email: sroebuck@scorpiogold.com

Scorpio Gold Profile

Content here…..

[table “” not found /]

Colonial Coal International Corp.
Suite 200, 595 Howe Street,
Vancouver.
British Columbia
V6C 2T5
Canada
Telephone 0203 691 9454

Scorpio Gold receives approval for their amendment to Mineral Ridge plan

Scorpio Gold {TSX.V:SGN} report BLM approval for their amended plan of operations for their Mineral Ridge deposit, located in Nevada.

This allows mining of the previously unmined Bluelite and Solberry pits.

Comment

Yet another piece of good news for Scorpio Gold, and another piece of the puzzle falls into place.

This approval allows for the mining of the satellite pits later this year (Q2)

One would hope this will increase production guidance for this year, along with the use of the Goldwedge mill for grinding the higher grade material increasing recovery at Mineral Ridge.

News Release

2015-04-21 – Mr. Steve Roebuck reports

Scorpio Gold {TSX: SGN} reports a favourable decision from BLM for amended plan of operations at their Mineral Ridge operation, located in Nevada.

The Bureau of Land Management Tonopah field office has issued a decision record and finding of no significant impact for the environmental assessment of Scorpio Gold Corp.’s Mineral Ridge

mine – Mary LC satellite deposit project amendment at Scorpio Gold's Mineral Ridge operation, located in Nevada. The BLM news release is available on-line.

Scorpio Gold's 70-per-cent-owned U.S. subsidiary, Mineral Ridge Gold LLC, submitted an amendment to the plan of operations to increase the surface disturbance at Mineral Ridge from approximately 612 acres to approximately 906 acres (448 acres BLM-administered land; 458 acres private land) to facilitate the development of the previously authorized Mineral Ridge mine project operations. The major components of the proposed activities include: expansion of the plan of operations boundary; addition to operations of the Bluelite and Solberry pits; addition of two new waste rock disposal areas; addition of a physical barrier to public access near the crusher; and reallocation and increase of exploration disturbance areas.

Peter J. Hawley, chief executive officer, reports: "*We are very pleased that our amendment to the plan of operations has been accepted by the state and federal regulators. I would like to thank everyone involved from the Nevada Division of Environmental Protection, Bureau of Land Management and the various contractors who all came together and assisted the Mineral Ridge staff in this process. This approval allows us to move forward with our scheduled mining at the Bluelite and Solberry pits in Q2 2015. Unique to the Bluelite and Solberry deposits is that neither has been mined before, hence their high-grade core zones are preserved and expected to positively impact the grade of ore being processed at both Mineral Ridge and the company's 100-per-cent-owned Gold wedge mill facility.*"

We seek Safe Harbor.

Inovio and Roche initiate clinical trial for chronic hepatitis B infection

Inovio Pharmaceuticals {NASDAQ: INO} and **Roche** are to Initiate Clinical Trials for Inovio's DNA Immunotherapy To Treat Chronic Hepatitis B Infection

This trial triggers a $3 million milestone payment to Inovio from Roche as part of their 2013 agreement to jointly develop INO's Hepatitis B immunotherapy.

Comment

Inovio are certainly generating lots of positive news releases, and positive ones at that.

Here once again is a partnership with a blue chip partner of substance, and generating cash for Inovio via milestone payments.

This positive newsflow is probably the reason the shareprice has risen from its March low of $6.50 by 60% to yesterday's $10.32!

News release

PLYMOUTH MEETING, Pa. – April 21, 2015 – **Inovio Pharmaceuticals, Inc. (NASDAQ: INO)** announced today that it has initiated a phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche and Inovio entered into a

partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3 million milestone payment from Roche to Inovio.

This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.

Dr. J. Joseph Kim, President and CEO, said, "*We are pleased our partnership has achieved this initial clinical advance emanating from the collaborative efforts at Roche and Inovio. While this is primarily a safety study, we will also investigate our therapy's impact on antibody and T-cell responses, which will help advance the product into further trials. Recent developments have seen several successful drugs built on hepatitis C treatments. Hepatitis B has a prevalence nearly double that of hepatitis C and antiviral treatment can control but usually does not eliminate the virus. A successful immunotherapy for hepatitis B holds significant potential*."

About INO-1800 for Hepatitis B

Inovio has reported pre-clinical data showing its hepatitis B immunotherapy (INO-1800) generated strong T-cell and antibody responses that led to the elimination of targeted liver cells in mice. These results indicate that the immunotherapy may have potential in the treatment of hepatitis B infection. In a

pre-clinical study, researchers found hepatitis B-specific T-cells exhibited a killing function, and could migrate to and stay in the liver and cause clearance of target cells without evidence of liver injury. This was the first study to provide evidence that intramuscular immunization can induce killer T-cells that can migrate to the liver and eliminate target cells.

Hepatitis B and Liver Cancer

One of the major causes and risk factors for liver cancer is infection by hepatitis B. The virus is extremely infectious – 100 times more so than HIV – and 240 million people are chronically infected worldwide. Hepatitis B contributes to an estimated one million deaths worldwide each year. Liver cancer is the third most common cancer and the most deadly, killing most patients within five years of diagnosis. About 600,000 new cases arise each year.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba. For more information, visit www.inovio.com.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com

N.B.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will

provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Nymox Announces New NX-1207 Prostate Cancer Clinical Trial Results

Nymox Pharmaceutical {NASDAQ: NYMX} today announced new results from the company's latest phase 2 trials for it's NX-1207 prostrate cancer study.

CEO Paul Averback The company were pleased to note the new results demonstrate "*the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a*

significant tangible benefit "

Comment

These new results explain the reason for the recent sharp price rise, where the price has trebled from around 60c to $1.80!

The fact that such a rise occurred prior to the news release in not good, and suggests that some people expected it.

News Release

HASBROUCK HEIGHTS, N.J., April 20, 2015 **Nymox Pharmaceutical Corporation {Nasdaq:NYMX}** announced today long-term clinical trial results from the Company's NX-1207 Phase 2 prostate cancer study NX03-0040. *The new results demonstrate statistically significant (p=.0067) better outcomes at up to 2.8 years for NX-1207 treated patients compared to controls.* Trial participants included 146 patients with low grade localized prostate cancer at 44 U.S. investigational sites.

A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers. The study found that after up to 2.8 years for NX-1207 single-injection treated patients there was a 68.2% reduction compared to controls in the proportion of patients who had upgraded blinded biopsy results in the treated area and went on to require and receive radiation therapy and/or prostatectomy (surgery) (p=.0067). The new study also found that all instances of surgery or radiation, including elective cases without upgrades, were decreased by 62.7% (p=.0035) in NX-1207 patients compared to the randomized control group.

Long-term clinical outcome is a highly important measure of

drug treatment efficacy. Patients were randomized to one of two doses of NX-1207 (2.5 mg or 15 mg) or to active surveillance (control). The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies, serial PSA measurements and long-term follow-up were performed on all patients treated and controls.

Paul Averback MD, CEO of Nymox said "*These new results show the potential of NX-1207 to offer men with the most common form of low-grade prostate cancer a significant tangible benefit in terms of avoidance of radiation and/or surgery and the related risks, discomforts, and permanent side effects. The results show a significant positive effect from a single painless injection which is very exciting*."

To date, NX-1207 has had an excellent safety profile. NX-1207 has shown safety in 9 clinical trials (BPH and prostate cancer) including repeat injection studies. The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.

One of the major problems with current prostate treatments for localized prostate cancer (radical prostatectomy, external beam radiation, or brachytherapy) is the relatively high incidence of reported sexual dysfunction post-treatment. In 9 studies, NX-1207 treatment has been shown to have no significant adverse effect post-treatment on sexual function or testosterone levels.

Prostate cancer is the most commonly diagnosed cancer in men, other than skin cancer, and is the second leading cause of cancer death for men. Approximately 50% of newly diagnosed prostate cancers are initially considered low risk.

For more information please contact info@nymox.com or 800-936-9669.

This press release contains certain "forward-looking

statements” as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Development of drug products involves substantial risks and actual results may differ materially from expectations. Factors that could cause actual results or events to differ materially from those projected in forward-looking statements are detailed from time to time in Nymox’s filings with the United States Securities and Exchange Commission and other regulatory authorities.

CONTACT: For Further Information Contact:
Paul Averback
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

City Investors Circle London evening presentation – Wednesday 22nd April

City Investors Circle announce an evening investor presentation with a mining theme in London on Wednesday April 22nd.

For full details and registration, please email – Rhea@city-investors-circle.com

Terrace Energy reports continuing progress and drill results

Terrace Energy reports additional well results and continuing progress on its STS Olmos Development Project.

COO George Morris “pleased with the results of our six wells”

Vancouver, April 14, 2015 – **Terrace Energy Corp. {TSXV: TZR}** reports continuing positive results and progress on its STS Olmos Development Project in McMullen and LaSalle Counties, Texas.

The Company previously reported initial flow back testing reports on the second three-well pad, the STE #1-5H, #2-5H and #3-5H pad at a combined initial rate of 2,821 BOEPD. Stabilized 30 Day Average IP rates are now reported at a combined total of 2,478 BOEPD as follows:

STE #1-5H 694 BOPD, 1172 MCFD (889 BOEPD*)
STE #2-5H 554 BOPD, 923 MCFD (708 BOEPD*)
STE #3-5H 698 BOPD, 1101 MCFD (881 BOEPD*)
These wells have now been on production for approximately 40 days have produced a total of approximately 100,000 BOE.

George Morris, the Company’s Sr. Vice President and COO, stated “We continue to be pleased with the results of our new wells. The six wells completed to date in our pad drilling program continue to meet or exceed our model expectations. We have demonstrated excellent, repeatable performance results across the field. The STS Project provides a stable,

profitable and predictable growth platform for the Company.”

Progress continues as planned on the overall development of the project. Drilling operations have been successfully concluded on two additional three-well pads. These six wells in McMullen County have been successfully drilled and cased in the Olmos Formation with lateral lengths averaging 5,400 feet. Based on the successful experience with the first two pad developments, fracture stimulation programs are being refined and optimized. In order to take advantage of favorable market conditions, the Company’s partner is rebidding stimulation and related services and will finalize schedules accordingly. The obligations under the existing drilling rig contract have also been fulfilled. We are currently demobilizing the current rig and are exploring options and timing to reinitiate the drilling program as market conditions dictate.

The Company, through its wholly owned subsidiary Terrace STS, LLC, holds a 15% interest in the above mentioned new wells on the STE pad and 27% working interest in the majority of the field acreage including the next six completions.

About Terrace Energy

Terrace Energy is an oil & gas development stage company that is focused on unconventional oil extraction in onshore areas of the United States.

ON BEHALF OF THE BOARD OF DIRECTORS

“Dave Gibbs”

Dave Gibbs, CEO

* BOEs may be misleading, particularly if used in isolation. A BOE conversion ratio of 6 Mcf: 1 bbl is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead.

** The results observed are not necessarily indicative of long-term production performance or the ultimate recovery from these wells

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Forward-Looking Information

This press release includes forward-looking information and forward-looking statements (together, “forward-looking information”) within the meaning of applicable Canadian and United States securities laws. Forward-looking information includes, but is not limited to: information regarding plans for the development of the Company’s projects and the timing thereof, including the potential number of drilling locations on the STS Olmos Development Project and expectations regarding achieving key successes and milestones over the next several months. Users of forward-looking information are cautioned that actual results may vary materially from the forward-looking information disclosed in this press release. The material risk factors that could cause actual results to differ materially from the forward-looking information contained in this press release include changes to the Company’s ability to access infrastructure in the vicinity of its projects at a reasonable price; changing costs for and availability of required goods and services; regulatory changes; risks relating to disagreements or disputes with joint venture partners, including any failure of a joint venture partner to fund its obligations; volatility in market prices for oil and natural gas; and all of the other risks and uncertainties normally associated with the exploration for and development and production of oil and gas, including geologic uncertainties, unforeseen drilling hazards, geological, technical, drilling and processing problems, accidents and adverse weather conditions. The forward-looking information

contained in this press release represents management’s best judgment of future events based on information currently available. The material assumptions used to develop the forward-looking information include: that the Company will be able to access infrastructure in the vicinity of its projects on reasonable terms; that the Company will be able to access the goods and services necessary in order to conduct further exploration, development and production at its projects on reasonable terms; that regulatory requirements will not change in any material respect; and that other aspects of the Company’s operations will not be affected by unforeseen events. Statements regarding future drilling locations are based on geologic interpretations which are subject to revision as further data is developed. The Company does not assume the obligation to update any forward-looking information, except as required by applicable law.

SOURCE Terrace Energy Corp.

For further information: terrace@terraceenergy.net, www.terraceenergy.net; Canadian Address: Suite 1012-1030 W Georgia St., Vancouver, B.C. V6E 2Y3, Ph: 604 282-7897, Fax: 604 629-0418; US Address:Suite 400-202 Travis Street, Houston, Texas 77002, Ph: 713 227-0010

City Investors Circle – Presentation in London next week

City Investors Circle are running an evening presentation with a mining theme next Tuesday, 21st April, in the financial district of the City of London.

The evening commences at 18.00 for 18.30, and the presentation will be followed by complimentary wines and a selection of wonderful hot and cold canapes.

For full details and venue, please email rhea@city-investors-circle.com

The audience limit for this event is 50 people, so early registration is advised.

El Niño Ventures and MMG terminate agreement – DRC saga continues

El Niño Ventures Inc. {TSX.V: ELN} and African Investments Ltd. announce a termination of their agreement by mutual consent.

The long running saga involving El Niño's DRC assets at Kasala continues, a solution seems as far away as ever.

Comment

This seemingly interminable dispute between EL Niño and their former partner in the DRC, GCP Group, continues to drag on.

El Niño, having won in the courts in the DRC, and then again in Canada when, GCP Group appealed the decision there, are now facing futrther actions, it is quite incredible that this legal dispute is still dragging on.

Quite how much longer El Niño can continue to fund the legal dispute must be a key question now. Maybe GCP have deeper

pockets and are prepared to wait in the hope ELN won't be baleto continue financing, and take it back by default?

News release

El Niño Ventures Inc. and MMG Africa Investments Limited, ("MMG") have mutually agreed to terminate the option agreement under which MMG would acquire the Company's 70% interest in the Kasala copper/cobalt permits located in the Democratic Republic of the Congo ("DRC") due to the uncertainty of disputed legal actions initiated by GCP Group ("GCP"), a minority shareholder of Infinity Resources Sprl ("Infinity"), the Company's Joint Venture Company.

ELN and MMG entered into an Option Agreement on 16 May 2014, whose terms required the Company to meet certain conditions precedent that would allow for MMG to begin an extensive exploration program on the Kasala project and potentially exercise the option to acquire ELN's 70% interest in the permits. Some conditions precedents are unfortunately incapable of being satisfied within the required time frame due to continued, questionable legal actions by GCP.

The Company would like to thank MMG and its management and legal team for its support and efforts in assisting ELN during the past year.

The Company is reviewing its position in continuing to support its endeavor to maintain ownership in the Kasala properties on its own or by joining with a third party.

On Behalf of the Board of Directors

Harry Barr

Chairman & CEO
El Niño Ventures Inc.

Further Information: Tel: +**1 604 685 1870**
Email: info@elninoventures.com

or visit

www.elninoventures.com
650-555 West 12th Avenue, City Square,

West Tower,

Vancouver, B.C.,

Canada, V5Z 3X7

Agnico Eagle acquires Soltoro

Soltoro {TSX.V: SOL} have announced they havebeen acquired by **Agnico Eagle Mines Ltd {TSX.V: AEM}**
The scheme of arrangement agreed gives a premium of 51% to the recent price of Soltoro's shares, and also gives shareholders shares in a new company, "spinco", to be floated and given to Soltoro's shareholders.

Toronto (April 10, 2015) – **Soltoro {TSX-V:SOL}** announced that it has entered into a definitive agreement on April 10, 2015 with **Agnico Eagle Mines Limited {NYSE:AEM, TSX:AE}** , pursuant to which Agnico Eagle will acquire 100% of Soltoro's issued and outstanding common shares, including shares issuable upon the exercise of outstanding options and warrants for total consideration of approximately C$31.6 million or approximately C$0.325 per Soltoro common share (based on Agnico Eagle's volume-weighted average price per share on the TSX for the five trading days ended April 9, 2015).Soltoro shareholders will be entitled to receive, in respect of each Soltoro common

share held, 0.00793 of an Agnico Eagle common share, C$0.01 in cash and one common share valued at C$0.02 per share of a company to be newly formed and spun off to Soltoro's shareholders under the proposed arrangement ("SpinCo"). The transaction will proceed by plan of arrangement under the Canada Business Corporations Act.The offer represents a premium of approximately 51% to the volume weighted average price of Soltoro common shares on the TSX Venture Exchange for the 20 day period ended April 9, 2015 and a premium of 55% to the last trading day prior to the announcement of the transaction.
As a result of the transaction, Agnico Eagle will acquire the El Rayo, El Tecolote, La Tortuga, San Pedro and Quila exploration projects held by Soltoro in the state of Jalisco, Mexico.

Soltoro will transfer to SpinCo the assets and related liabilities associated with the Gavilan, El Santuario and Chinipas exploration properties currently held by Soltoro that are located outside of the state of Jalisco, Mexico. SpinCo will initially be capitalized with approximately C$2.0 million in cash contributed by Agnico Eagle. ***The SpinCo shares to be received by Soltoro shareholders will not be listed on any stock exchange and will not be eligible investments for RRSPs or other registered plans under the Income Tax Act (Canada).***

Andrew Thomson, President and CEO of Soltoro stated: *"Soltoro's focus has been to deliver value to its shareholders by spending the majority of its funds in the ground in order to make discoveries and pursue development of its assets. This transaction secures the continued advancement of Soltoro's main projects in Jalisco by Agnico Eagle while also facilitating shareholders' continued participation in the balance of its exploration assets through their ownership of SpinCo shares. As shareholders participating in this transaction, we look forward to the development of Agnico Eagle's portfolio of operating and development stage projects in Mexico and believe this transaction confirms the untapped exploration potential of south western Mexico.*

*The SpinCo entity will also provide Soltoro shareholders with the potential opportunity to participate in future exploration efforts in Mexico with members of our existing management team. I would like to thank our entire team for all their tireless efforts and our shareholders for their suppor*t."

Before entering into the Agreement, the Soltoro Board of Directors established a Special Committee comprised of independent directors, Douglas Reeson, Phillip Walford and William McGuinty (Chair), to oversee and supervise the process carried out by Soltoro in negotiating the Agreement and to advise the Soltoro Board with respect to any recommendation that the Soltoro Board should make to Soltoro securityholders. The Soltoro Board has received an opinion from its financial advisor that (subject to the assumptions, limitations and qualifications set out in its opinion) the consideration offered under the Arrangement is fair, from a financial point of view, to Soltoro security holders.

Both the Soltoro Board and the Special Committee have unanimously determined that the Arrangement is fair, from a financial point of view, to Soltoro security holders and in the best interests of Soltoro and its shareholders and unanimously recommend that Soltoro securityholders vote in favour of the Arrangement.

Under certain circumstances where the transaction is not completed, Soltoro has agreed to pay Agnico Eagle a termination fee of C$1.0 million.

Soltoro has also provided Agnico Eagle with certain other deal protections, including customary non-solicitation covenants and a five business day right to match any superior proposal.

All of the directors and officers and the largest shareholder of Soltoro, who hold in the aggregate approximately 29% of the issued and outstanding Soltoro shares on a partially-diluted basis (assuming the exercise of all outstanding warrants and in-the-money options) have entered into support agreements with Agnico Eagle pursuant to which they have agreed, among other things, to support the transaction and vote all of their Soltoro securities in favour of the Arrangement, subject only to limited exceptions. Any options or warrants that remain unexercised at the effective time of the Arrangement will be cancelled without payment. Each of Soltoro's directors and officers has entered into non-competition and non-solicitation agreements pursuant to which they have agreed not to compete with the business of Soltoro or acquire any properties or interests surrounding defined perimeters of the Soltoro properties in the state of Jalisco for a period of two years from the effective date of the Arrangement.

The Arrangement is subject to the approval of Soltoro securityholders by a two-thirds vote and by approval of a majority of the minority shareholders of Soltoro in accordance with MI 61-101, and approval by the court and stock exchanges.

Full details of the Arrangement will be set out in Soltoro's management information circular that will be prepared in respect of the meeting of security holders to approve the Arrangement. Soltoro intends to mail the information circular within four weeks and to hold its securityholders' meeting in early June, 2015. The transaction is expected to close in June, 2015.

Concurrently with the signing of the Agreement, Agnico Eagle made a loan to Soltoro in the amount of C$925,000 for specified working capital purposes (the "Loan"), evidenced by a promissory note executed by Soltoro and its Mexican operating subsidiary, jointly and severally as debtors, in favour of Agnico Eagle.

The Loan is repayable on April 10, 2016 or upon an “Event of Default”. Interest on the Loan is payable at the rate of 7.850% per annum upon maturity, together with all principal and other amounts owing under the Loan. Events of Default include a breach or failure of Soltoro to perform, observe or comply with any of the covenants or obligations contained in the Agreement or the Promissory Note, the termination of the Agreement, and other customary events.

The Loan may be repaid in cash at any time by Soltoro without penalty. In certain limited circumstances and subject to conditions contained in the Promissory Note (including the requirement to obtain TSXV approval), principal, interest and other amounts owing under the Loan may be repaid in Soltoro common shares at the option of Soltoro at 95% of the volume weighted average price of Soltoro common shares on the TSXV for the 20 trading days immediately preceding the repayment date.

Soltoro and Agnico Eagle are at arm’s length, and there are no finder’s fees payable in relation to the Agreement.

Soltoro has retained Maxit Capital LP as its financial advisor including delivering the fairness opinion, and WeirFoulds LP as legal advisor in connection with the transaction; Agnico Eagle has retained Red Cloud Mining Capital Inc. as its advisor and Davies Ward Phillips & Vineberg LLP as legal advisor in connection with the transaction.

Copies of the Agreement, support agreements, management information circular and related proxy materials, Promissory Note and other related documents will be filed with securities regulators and will be available on SEDAR at www.sedar.com.

About Soltoro

Soltoro is engaged in exploration for gold and silver deposits in Mexico. Soltoro holds in excess of 30,000 hectares of ground in Jalisco State and has been focused on expanding

silver resources at the El Rayo silver project while seeking partners to advance the balance of its projects. Soltoro holds 4 properties in Mexico outside of Jalisco state which will form the foundation for SpinCo. Soltoro has 75,533,037 common shares issued and outstanding and trades on the TSX Venture Exchange under the symbol “SOL”.

For further information regarding Soltoro, contact:
Andrew Thomson, President and CEO at
(1 416 987-0722 or visit www.soltoro.com.

Forward-Looking Statements
The information in this document has been prepared as at April 10, 2015. Certain statements contained in this document constitute forward looking information under the provisions of Canadian provincial securities laws and are referred to herein as forward-looking statements. When used in this document, the words “anticipate”, “believe”, “expect”, “estimate”, “forecast”, “intend”, “will”, “planned”, and similar expressions are intended to identify forward-looking statements or information. Such statements include without limitation: statements regarding the offer price, timing, closing and approval of the transactions contemplated by the Agreement and the satisfaction of all conditions necessary in order to complete the Arrangement; the realization of all anticipated benefits of the Arrangement; statements regarding the number of Agnico Eagle shares issuable under the Arrangement; statements regarding the quality or potential of Soltoro’s properties; statements regarding the ability of Agnico Eagle to advance Soltoro’s projects within the Guachinango district or regarding the ability of SpinCo to advance the properties to be acquired by SpinCo under the Arrangement; statements regarding the potential and value of SpinCo and the SpinCo shares; statements as to the projected

development of certain ore deposits, including estimates of exploration, development and production; and statements regarding anticipated future exploration. Such statements and information reflect Soltoro's view as at the date of this document and are subject to certain risks, uncertainties and assumptions, and undue reliance should not be placed on such statements and information. Many factors, known and unknown could cause the actual results to be materially different from those expressed or implied by such forward looking statements. Such risks include, but are not limited to: the volatility of prices of gold and silver and other metals; uncertainty of mineral reserves, mineral resources, mineral grades and mineral recovery estimates; uncertainty of future exploration, development or production, uncertainty concerning capital and budgeted expenditures and contingent liabilities and Soltoro's ability to repay the Loan if required, and other fees and costs; currency fluctuations; financing of additional capital requirements; cost of exploration and development programs; mining risks; community protests; risks associated with foreign operations; governmental and environmental regulation; the volatility of stock prices; and risks associated with by-product metal derivative strategies. For a more detailed discussion of such risks and other factors that may affect Soltoro's ability to achieve the expectations set forth in the forward-looking statements contained in this document, see Soltoro's disclosure filed on SEDAR at www.sedar.com. Soltoro does not intend, nor does it assume any obligation, to update these forward-looking statements and information, other than as required by applicable law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

Inovio – Strong T cell results for head and neck cancer for HPV in small trial

Inovio Pharmaceuticals {NASDAQ: IMO} HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients

DNA-based immunotherapy generates strong immune responses similar to those in patients treated for cervical dysplasia

Comment

Inovio have published multiple news releases, all of them positive, in the last few days,and seem to be on an awareness campaign!

This latest news, to be fair, was on a very small patient sample, only 4 people, so early days, but it was positive in 75% of the cases, so that at least is a positive they can take to the next level, and they intend to extend to up to 20 patients.

The main purpose of the limited test is to assess patient safety and tolerability.

News release

Plymouth Meeting. – April 9, 2015 – **Inovio Pharmaceuticals, Inc. {NASDAQ:INO}** announced today preliminary data showing that its INO-3112 DNA-based immunotherapy generated strong CD8+ T cell responses in 3 of 4 patients with head and neck cancer associated with human papillomavirus (HPV) types 16 and 18. INO-3112, an active immunotherapy that targets HPV 16 and 18 and simultaneously expresses IL-12, is designed to activate in vivo (in the body) immune responses to antigens from high risk HPV types and eliminate precancerous and cancerous cells displaying these antigens. The data, which are T cell measurements from the first four treated patients of this phase I/IIa study, are being presented today at the World Vaccine Congress 2015 by Inovio's COO, Dr. Niranjan Y. Sardesai.

These positive results represent the first study and first report of T cell immune responses generated in cancer patients after treatment with an Inovio DNA immunotherapy. The magnitude and characteristics of these interim immune response data mirror immune responses previously observed in human studies of VGX-3100 for HPV-associated cervical dysplasia; in a placebo-controlled phase II study, strong T cell immune responses were positively correlated with achievement of primary and secondary efficacy endpoints.

Dr. J. Joseph Kim, Inovio's President and CEO, said, *"This initial data set from Inovio's first cancer study provides encouraging evidence that we are on an important path to better optimized immunotherapy products. Regardless of whether it is an infectious disease, a precancer, or a cancer: the immune system uses the same mechanism to eliminate infected or mutated cells. In immune-oncology, it's all about the T cells. Here we show in cancer patients that we can generate antigen-specific CD8+ killer T cell responses, which are essential to an effective immunotherapy.*

“We look forward to completing our currently enrolling studies for HPV-associated head & neck and cervical cancers, completing the preparations for our planned phase III study for cervical precancer, and launching new studies for hepatitis B and prostate cancer that all rely on the same targeted T-cell-based killing activity.”

This open label study of HPV-caused head and neck cancer is intended to assess the safety, tolerability, and immunogenicity of INO-3112 in up to twenty adults with HPV-positive head and neck squamous cell carcinoma. The study (NCT02163057) includes patients who are being treated with INO-3112 before and after resection of their tumor as well as patients being treated with INO-3112 after completion of chemotherapy and radiation therapy.

About HPV-Caused Head & Neck Cancer

Human papillomavirus (HPV) is the most common sexually transmitted disease in the United States, infecting 79 million Americans. HPV is known to play a major role in the development of head and neck cancers, which include cancers of the oral cavity, oropharynx, nose/nasal passages and larynx. Head and neck cancers associated with HPV account for nearly 3 percent of all cancers in the United States and are twice as prevalent in men as in women. Incidence rates of HPV-caused head and neck cancers have been on the rise, especially HPV-associated oropharyngeal cancer in men, and are expected to continue growing. By 2025, researchers believe that HPV will be the causative factor of 90% of all head/neck cancers.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate

best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. With an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. Partners and collaborators include Roche, MedImmune, University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, and University of Manitoba.

For more information, visit www.inovio.com.

CONTACTS:

Investors: Bernie Hertel. – bhertel@inovio.com

Inovio Pharmaceuticals. – 858-410-3101

* * *

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines, our expectations regarding our research and development programs and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, including safety and efficacy for VGX-3100, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies),

the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, our ability to support our broad pipeline of SynCon® active immune therapy and vaccine products, our ability to advance our portfolio of immune-oncology products independently, including INO-5150, and to commence a phase I clinical trial for INO-5150 in the first half of 2015, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, our ability to enter into partnerships in conjunction with our research and development programs, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

Scorpio Gold high grade intersects at Solberry Deposit, Mineral Ridge

Scorpio Gold {TSX.V: SGN} has released the final drill holes from their 2014 drill program a Solberry Satellite Deposit, located at their Mineral Ridge project in Nevada.

The RC drill holes encountered some high grade mineralisation, and indcate the potential to increase the LOM.

Comment

Scorpio had an excellent drill program in 2014, and these results add to those already released. Once again they have delivered high grade intersects, and the potential to increase the LOM beyond the current term.

Credit has to be given to management here, they have delivered in spades in 2014, paid of all their debt, and just raised $15 million from a quality financier in an incredibly tough market!

Not many companies in the junior mining sphere have accomplished anyhting like this in the last year, most are cash constrained, unable to drill their projects, and looking to hang on by their fingertips until the market for such companies turns, and that may take more time than they have!

Official News release

Scorpio Gold Intersects 12.54 g/t gold over 15.91 meters at the Solberry Satellite Deposit, Mineral Ridge Project, Nevada
Vancouver, April 8, 2015 – **Scorpio Gold Corporation {TSX-V:**

SGN} reports their final results from its 2014 expansion drilling program on the Solberry deposit at the 70% owned Mineral Ridge project, located in Nevada.

The 2014 drilling program was very successful and included both infill and step-out drilling to the modelled pit shell outline for Solberry that was presented in the updated Life of Mine Plan for the Mineral Ridge operation (as reported in the Company's July 21, 2014 news release). **Management believes that results from the 2014 program will lead to an upgrade and expansion of the mineral resources currently defined for the Solberry deposit and potentially extend life of mine.**

In addition to reverse circulation ("RC") drilling on Solberry, two HQ diameter core holes were collared adjacent to RC hole MR14929 to provide detailed geological data in an area of high-grade mineralization. The results from RC hole MR14929 were previously released on June 16, 2014. Core hole MR14985 was drilled vertically to directly twin MR14929, whereas core hole MR14986 was oriented to the west at a -65 degree dip. A very good correlation of results is noted for the twinned holes as follows:

Table 1. Solberry Deposit –RC Hole MR14929 & Core Hole MR14985

Hole No.	Azm (deg)	Dip (deg)	From (ft)	To (ft)	Width (ft)	From (m)	To (m)	Width (m)	Gold (OPT)	Gold (g/t)
MR14929	0	-90	45	110	65	13.72	33.53	19.81	0.354	12.15
MR14985	0	-90	44.9	97.1	52.2	13.69	29.60	15.91	0.366	12.54

Highlights of the final results from the 2014 expansion drilling on the Solberry deposit include:Logging of the core holes has allowed for a better understanding of the lithology and structural geology as well as the styles and controls to mineralization at Mineral Ridge.

- MR14936: 1.65 grams per tonne ("g/t") gold over 3.05 meters

- MR14939: 3.89 g/t gold over 3.05 meters
- MR14985: 12.54 g/t gold over 15.91 meters
- MR14986: 10.26 g/t gold over 2.65 meters
- MR141134: 1.95 g/t gold over 6.10 meters

A full table and drill hole location map is available at: http://bit.ly/1DMddmN

All holes presented were completed by reverse circulation (RC) drilling with the exception of two core holes, MR14985-6. True width is estimated at 80-100% of downhole width.

Analytical results were performed by American Assay Laboratory Inc. in Sparks, Nevada, an ISO/IEC 17025:2005 accredited facility. External check assays to verify lab accuracy are routinely completed by ALS Chemex, an ISO 9001:2000 certified and ISO/IEC 17025:2005 accredited facility. Further details are presented in the Company's quality assurance and quality control program for the Mineral Ridge project at: MR QAQC.

About Scorpio Gold

Scorpio Gold holds a 70% interest in the producing Mineral Ridge gold mining operation located in Esmeralda County, Nevada with joint venture partner Waterton Global Value L.P. (30%), and **Scorpio Gold is currently entitled to receive 80% of cash flow generated.**

Mineral Ridge is a conventional open pit mining and heap leach operation. The Mineral Ridge property is host to multiple gold-bearing structures, veins and lenses at exploration, development and production stages. Scorpio Gold also holds a 100% interest in the advanced exploration-stage Goldwedge property and processing facility in Manhattan, Nevada. The Company is assessing its exploration plans for the Goldwedge property as well as the potential for toll milling at the Goldwedge plant, which is currently permitted for 400 tons per day.

Scorpio Gold's President, Steve Roebuck, PGeo, is a Qualified

Person as defined by National Instrument 43-101 and has reviewed and approved the content of this release.

ON BEHALF OF THE BOARD
SCORPIO GOLD CORPORATION

Peter J. Hawley,
CEO

Inovio selected by DARPA to lead $45 million Ebola Project

Inovio Pharmaceuticals {NASDAQ: INO} has been selected by **DARPA** to Lead a $45 Million Program to Expedite Development of Novel Products to Prevent and Treat Disease Caused by Ebola.

Funding Will Accelerate Development of Inovio's DNA-Based Monoclonal Antibodies That Could Offer Product Development, Manufacturing, Scale-Up and Dosing Benefits

Comment

The award of this important and prestigious project for Inovio to lead signifies a huge vote of confidence on the part of the US authorities in the quality of the work Inovio has achieved in the past.

The list of collaborators to the project testify the significance of the respect the industry has for their work.

Official news release

PLYMOUTH MEETING – April 8, 2015 – **Inovio Pharmaceuticals Inc.{Nasdaq:INO}** announced today that the company has been selected to receive a grant from the ***Defense Advanced Research Projects Agency (DARPA)*** to lead a collaborative team to develop multiple treatment and prevention approaches against Ebola. Inovio is the prime contractor on the DARPA program.

Other collaborators are: MedImmune, the global biologics research and development arm of AstraZeneca; GeneOne Life Sciences (KSE:011000) and its manufacturing subsidiary, VGXI, Inc.; and Professor David B. Weiner, PhD, professor of Pathology and Laboratory Medicine at The Perelman School of Medicine at the University of Pennsylvania, Emory University and Vanderbilt University.

The Inovio-led consortium is taking a multi-faceted approach to develop products to prevent and treat Ebola infection. These programs include development and early clinical testing of a therapeutic DNA-based monoclonal antibody product dMAb™ against the Ebola virus infection.

This promising new technology has properties that best fit a response to the outbreak in that they could be designed and manufactured expediently on a large scale using common fermentation technology, are thermal-stable, and may provide more rapid therapeutic benefit.

A highly potent conventional protein-based therapeutic monoclonal antibody (mAb) product against Ebola virus infection.

Inovio’s DNA-based vaccine against Ebola, with the first patient expected to be dosed in 2Q 2015. In previously published preclinical testing, Inovio’s DNA-based Ebola vaccine protected 100% of vaccinated animals from death and sickness after being exposed to a lethal dose of the Ebola

virus.

Pathogen specific mAbs have emerged as a viable approach for immunoprophylaxis against Ebola and other pathogens where anti-viral drugs or vaccinations are not currently available. mAbs can be administered either just before or just after exposure to the pathogen and serve to combat the immediate effects of the pathogen. Unlike vaccines, immunoprophylaxis by mAbs does not develop long term immune memory. Therefore an ideal approach would include the administration of a mAb for immediate protection and a vaccine to train the immune system for longer term protection.

Previous Ebola research studies have shown that monoclonal antibodies (such as ZMapp) could be useful in treating patients who have been infected with Ebola virus by selectively binding and neutralizing the virus in the body. Inovio is already developing dMAb products against influenza and antibiotic resistant bacteria as a subcontractor under a separate DARPA funded grant.

The proposed effort will cover pre-clinical development costs for the dMAb products and protein mAb candidates as well as GMP manufacturing costs and the phase I clinical study costs with the three product candidates. MedImmune will manufacture the protein mAbs and the Inovio-GeneOne/VGXI team will manufacture the DNA based products. The academic partners are leading Ebola research and medical centers at the front edge of the discovery efforts for highly potent anti-Ebola mAbs. The funding period is over two years and covers a base award of $21 million and an option award of $24 million. The development proposal includes a second option of $11 million to support additional product supply and clinical development activities. The options are contingent upon the successful completion of certain pre-clinical development milestones.

Due to the global concerns and immediacy of need, the consortium has employed an aggressive development timeline for

the Ebola products by developing these three options in parallel, resulting in an acceleration of the initial clinical evaluation. None of these products will contain any Ebola virus or viral particles.

Dr. J. Joseph Kim, President and CEO of Inovio, said, "*We thank DARPA for their confidence in Inovio to address this medical crisis by simultaneously developing a preventive Ebola vaccine and treatment for those infected. We are advancing against this virus on all fronts. The development of the novel DNA-based monoclonal antibodies hold the greatest potential benefit in their speed of manufacturing, dosing and stability, and we are pleased to add them to our strong product pipeline*."

Dr. Niranjan Y. Sardesai, COO of Inovio and the DARPA Ebola Program Team Leader, said, "*This is an exciting government–academia–industry partnership bringing together global product development experts to rapidly develop and test novel dMAb products against Ebola. Our optimized DNA based product programs are uniquely placed to target both rapid immunity through delivery of dMAb products as well as long-term immunity via DNA vaccination. Success in any one of the three parallel approaches by the team will be a boost to the global efforts against the Ebola virus*."

DARPA, an agency of the U.S. Department of Defence that creates and supports novel technologies important for national security, has selected Inovio to develop products that if successful can add to the arsenal of rapid response capabilities. Inovio's Ebola program is initially targeted to treat first responders and Ebola-infected health care workers and patients, but could potentially be widely utilized to stem the spread of the current or subsequent outbreaks.

Inovio and the other participating institutions have a strong history of previous collaborative development efforts having worked together on multi-institutional product development

grants and contracts bringing new products to the clinic. Inovio’s previous collaborative Ebola vaccine research efforts with GeneOne Life Sciences have been incorporated into this Inovio-led team.

About the Ebola Virus

The Ebola virus causes periodic outbreaks of a highly contagious and lethal human infectious disease marked by severe haemorrhagic fever, with a mortality rate that ranges between 50% and 90%. The infection typically affects multiple organs in the body and is often accompanied by severe bleeding. The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission. At present, there are no FDA-approved pre- or post-exposure interventions available in the event of an outbreak, laboratory accident, or deliberate misuse. The Ebola virus is classified as a Category A Priority Pathogen by the Centres for Disease Control and Prevention. This designation prescribes an accelerated development pathway for FDA approval that determines efficacy based on two different validated animal studies followed by clinical evaluation in phase 1 and phase 2 trials to establish safety and immunogenicity for use in humans.

CONTACT: Investors: Bernie Hertel, Inovio Pharmaceuticals

- 001 858-410-3101
- bhertel@inovio.com

Inovio presentation at Regenmed Investor Day – New York City

Inovio Pharmaceuticals {NASDAQ: INO} presented at the prestigious Piper Jaffray sponsored 3rd annual Regenmed investor conference in New York City.

This video of the presentation, was made to the conference on the 25th March 2015, and features COO Niranjan Sardesai.

The 3rd Annual Regenmed conference took place in New York City on the 25 March 2015.

Inovio was one of 32 presenting companies, from the regenerative medicine sector.

The video of the presentation can be seen here; http://bit.ly/1NUAxQF